1. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
- Author
-
Klootwijk, P., Lenderink, T. (Timo), Meij, S. (Simon), Melkert, R. (Rein), Umans, V.A.W.M. (Victor), Stibbe, J. (Jeanne), Muller, E.J., Poortermans, K.J., Deckers, J.W. (Jaap), Simoons, M.L. (Maarten), Boersma, H. (Eric), Klootwijk, P., Lenderink, T. (Timo), Meij, S. (Simon), Melkert, R. (Rein), Umans, V.A.W.M. (Victor), Stibbe, J. (Jeanne), Muller, E.J., Poortermans, K.J., Deckers, J.W. (Jaap), Simoons, M.L. (Maarten), and Boersma, H. (Eric)
- Abstract
AIMS: Thrombin plays a key role in the clinical syndrome of unstable angina. We investigated the safety and efficacy of five dose levels of efegatran sulphate, a direct thrombin inhibitor, compared to heparin in patients with unstable angina. METHODS: Four hundred and thirty-two patients with unstable angina were enrolled. Five dose levels of efegatran were studied sequentially, ranging from 0.105 mg. kg(-1). h(-1)to 1.2 mg. kg(-1). h(-1)over 48 h. Safety was assessed clinically, with reference to bleeding and by measuring clinical laboratory parameters. Efficacy was assessed by the number of patients experiencing any episode of recurrent ischaemia as measured by computer-assisted continuous ECG ischaemia monitoring. Clinical end-points were: episodes of recurrent angina, myocardial infarction, coronary intervention (PTCA or CABG), and death. RESULTS: Efegatran demonstrated dose dependent ex-vivo anticoagulant activity with the highest dose level of 1.2 mg. kg(-1). h(-1)resulting in steady state mean activated partial thromboplastin time values of approximately three times baseline. Thrombin time was also inc
- Published
- 1999
- Full Text
- View/download PDF